BackVigil Neuroscience Overview

Vigil Neuroscience EBIT

Latest ebit for VIGL: $-97M, below the sector sector average of $-6.4M.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$27.49M
22.3% YoY

As of Jun 30, 2025

Annual EBIT (TTM)

-$96.75M
7.28% YoY

Trailing 12 months ending Jun 30, 2025

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Vigil Neuroscience (VIGL) FAQ

As of the most recent data (June 2025), VIGL shows a EBIT of $-97M. That compares with $-90M in the prior-year period — down 7.3% year over year. That is below the sector sector average of $-6.4M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VIGL's EBIT is now $-97M (was $-90M) — a 7.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Vigil Neuroscience is outperforming or lagging.

The its sector sector average EBIT is about $-6.4M. Vigil Neuroscience is at $-97M, which is lower that average. That is roughly 1411.2% below the sector mean. Use the comparison chart on this page to see how VIGL stacks up against individual peers as well.

Tracking VIGL's ebit over time shows whether Vigil Neuroscience is scaling, shrinking, or reshaping that part of the business. The current reading is $-97M That compares with $-90M in the prior-year period — down 7.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Vigil Neuroscience's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-97M) with ownership activity and broader fundamentals.